雲頂新耀(01952.HK):NeflgArd關鍵性3期臨床試驗部分獲良好結果
雲頂新耀(01952.HK)公布,其合作夥伴Calliditas Therapeutics報告了全球3期臨床試驗NefIgArd A部分獲得良好結果,該試驗分析了Nefecon對比安慰劑治療199例原發性IgA腎病(「IgAN」)患者的療效。
該試驗達到了其主要目標,結果顯示在治療9個月後,患者的尿蛋白肌酐比率(或蛋白尿)在統計學上顯著降低,在治療12個月後,有了顯著的持續性改善。該試驗還達到了關鍵的次要終點,顯示治療9個月後,即與安慰劑相比,患者腎小球濾過率(eGFR)估計值存在統計學上的顯著差異。
療效資料也表明,在與進展為終末期腎病(ESRD)相關的關鍵因素上具有顯著且有益的效果。此外,結果顯示Nefecon的耐受性普遍良好。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.